(Supporting the Development of Heim Pál Children’s Hospital,)
Plexiform neurofibromas occurring in approximately 20–50% of all neurofibromatosis
type-1 (NF1) cases are histologically benign tumors, but they can be fatal due to
compression of vital structures or transformation to malignant sarcomas or malignant
peripheral nerve sheath tumors. All sizeable plexiform neurofibromas are thought to
result from an early second mutation giving rise to a loss of heterozygosity of the
NF1 gene. In this unusual case, a 12-year-old girl presented with a rapidly growing,
extremely extensive plexiform neurofibroma with segmental distribution over the entire
right arm, extending to the right chest wall and mediastinum, superimposed on classic
cutaneous lesions of NF1. After several surgical interventions, the patient was efficiently
treated with an oral selective MEK inhibitor, selumetinib, which resulted in a rapid
reduction of the tumor volume. Molecular analysis of the NF1 gene revealed a c.2326-2
A>G splice-site mutation in the clinically unaffected skin, peripheral blood sample,
and plexiform neurofibroma, which explains the general clinical symptoms. Furthermore,
a novel likely pathogenic variant, c.4933dupC (p.Leu1645Profs*7), has been identified
exclusively in the girl’s plexiform neurofibromas. This second-hit mutation can explain
the extremely extensive segmental involvement.